A new antifungal drug, voriconazole, causes patients to “develop a range of neurological side effects, including auditory and visual hallucinations,” within 24 hours to 2 weeks of beginning treatment. The drug is marketed as Vfend, and is administered intraveneously to treat serious fungal infections. The National Institute of Health has been testing the toxicity of the drug and reported the neurological side effects at a recent conference.
